New York-headquartered charity TB Alliance has announced a positive decision from the US regulator’s scientific advisory body, in relation to an investigational multidrug-resistant (MDR) tuberculosis therapy.
Founded in South Africa, TB Alliance is a non-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB).
The group has been testing pretomanid in combination with bedaquiline and linezolid to treat adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive MDR TB.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze